257 related articles for article (PubMed ID: 27151433)
1. The role of DOT1L in the maintenance of leukemia gene expression.
Wang X; Chen CW; Armstrong SA
Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
[TBL] [Abstract][Full Text] [Related]
2. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
3. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
4. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
5. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
6. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
7. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
8. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
Li BE; Ernst P
Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
[TBL] [Abstract][Full Text] [Related]
9. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
10. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
11. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
13. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
14. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
15. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
16. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
17. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
[TBL] [Abstract][Full Text] [Related]
18. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
[TBL] [Abstract][Full Text] [Related]
19. When epigenetics kills: MLL fusion proteins in leukemia.
Slany RK
Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
[TBL] [Abstract][Full Text] [Related]
20. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]